NCT06841640View on ClinicalTrials.gov

Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

May 20, 2025

Study Completion Date

June 7, 2025

Conditions
COPD
Interventions
DRUG

AERO-001

Open-label

DRUG

AERO-002

Open-label

DRUG

AERO-007

Double-blind

Trial Locations (1)

Unknown

Medicines Evaluation Unit Ltd, Manchester

Sponsors
All Listed Sponsors
lead

AeroRx Therapeutics Inc.

INDUSTRY